Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.

NCT02451111 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02451111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02451111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
November 6, 2015
Completion date
July 15, 2023
Enrollment
190 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma